Canaccord Genuity Raises Price Target on Insulet Corporation (PODD) to $399, Maintains Buy Rating

With significant upside potential, Insulet Corporation (NASDAQ:PODD) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds.

On September 29, given Insulet Corporation (NASDAQ:PODD)’s dominant position in the insulin pump industry and its first-mover advantage in the type 2 diabetes market, Canaccord Genuity increased its price objective for the company from $353 to $399 while keeping its Buy rating.

The company revised its 2025 and 2026 revenue forecasts to account for growth potential and a slight increase in operating margin. In an effort to set the company apart and celebrate user independence with its tubeless device, Insulet Corporation (NASDAQ:PODD) and Pantone collaborated earlier this month to introduce “Omnipod Mango,” a vibrant tropical orange-yellow color for their Omnipod insulin pump.

The partnership highlights Insulet Corporation (NASDAQ:PODD)’s emphasis on innovation and the customer experience, and the company’s leadership in diabetes care solutions is further cemented by the ongoing high demand for its Omnipod system.

Insulet Corporation (NASDAQ:PODD) is a U.S. and international company that develops, produces, and markets insulin delivery devices for individuals with insulin-dependent diabetes. It is one of the best quality stocks.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.